Mayne Pharma Group (HG6) Income Statement
Mayne Pharma Group Income Statement
Last quarter (Q4 2026), Mayne Pharma Group's total revenue was $171.61M, a decrease of 14.40% from the same quarter last year. In Q4, Mayne Pharma Group's net income was $39.41M. See Mayne Pharma Group’s key income statements, including revenue, expenses, profit, and income.
| Income Statement | Jun 26 | Jun 25 | Jun 24 | Jun 23 | Jun 22 |
|---|---|---|---|---|---|
| $ 383.68M | $ 408.10M | $ 388.15M | $ 183.59M | $ 157.15M | |
| $ 192.21M | $ 247.27M | $ 218.53M | $ 26.84M | $ 23.75M | |
| $ 226.49M | $ 270.87M | $ 357.59M | $ 213.28M | $ 145.62M | |
| Depreciation and Amortization | $ 63.69M | $ 69.27M | $ 68.46M | $ 65.44M | $ 55.18M |
| $ 29.40M | $ 47.24M | $ -116.93M | $ -193.80M | $ -78.88M | |
| $ -34.28M | $ -23.59M | $ -139.06M | $ -186.44M | $ -121.88M | |
| $ 70.04M | $ -59.70M | $ -51.02M | $ -83.25M | $ -23.71M | |
| $ 35.76M | $ -83.30M | $ -190.09M | $ -269.70M | $ -145.59M | |
| $ 24.47M | $ -93.84M | $ -174.23M | $ 117.25M | $ -281.29M | |
| Per Share Metrics | |||||
| Basic EPS | $ 0.31 | $ -1.14 | $ -2.19 | $ -3.89 | $ -3.46 |
| Diluted EPS | $ 0.21 | $ -1.14 | $ -2.19 | $ -3.89 | $ -3.46 |
| Weighted Average Shares Outstanding | 79.94M | 79.14M | 79.62M | 81.25M | 81.25M |
| Weighted Average Shares Outstanding (Diluted) | 106.29M | 79.14M | 79.62M | 81.25M | 81.25M |
Currency in AUD
